Herantis Pharma Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Herantis Pharma Oyj şirketinin toplam hissedar öz sermayesi €2.0M ve toplam borcu €30.0K olup, bu da borç-öz sermaye oranını 1.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €3.6M ve €1.6M dir.

Anahtar bilgiler

1.5%

Borç/özkaynak oranı

€30.00k

Borç

Faiz karşılama oranı	n/a
Nakit	€3.49m
Eşitlik	€2.04m
Toplam yükümlülükler	€1.61m
Toplam varlıklar	€3.65m

Son finansal sağlık güncellemeleri

Recent updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HRTIS 'nin kısa vadeli varlıkları ( €3.6M ) kısa vadeli yükümlülüklerini ( €1.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: HRTIS şirketinin kısa vadeli varlıkları ( €3.6M ) uzun vadeli yükümlülüklerini ( €25.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HRTIS şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: HRTIS 'nin borç/öz sermaye oranı son 5 yılda 279.5% seviyesinden 1.5% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: HRTIS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: HRTIS serbest nakit akışı her yıl % 5.7 1.6 yıl yetecek nakit akışına sahip olacaktır.

Herantis Pharma Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Herantis Pharma Applies for Delisting from Nasdaq First North Growth Market Sweden

Recent updates

Herantis Pharma Plc Starts Dosing of HER-096 in the Part 1 of the Phase 1b Clinical Trial

Herantis Pharma Oyj to Report Fiscal Year 2023 Results on Mar 27, 2024

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €4.506795 million.

Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096

Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study

Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096

Herantis Pharma Oyj Announces Submission of A Clinical Trial Application (CTA) for A Phase 1 Study for HER-096

Herantis Pharma Oyj to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Herantis Pharma Applies for Delisting from Nasdaq First North Growth Market Sweden

Less than half of directors are independent

Herantis Pharma Oyj to Report Second Half, 2022 Results on Mar 02, 2023

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €1.4625 million.

Herantis to Focus on HER-096

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology

Herantis Pharma Announces xCDNF Preclinical Candidate Selection

Earnings beat expectations

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Herantis Pharma Plc Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema

New 90-day low: €3.28

Herantis Pharma Oyj and Nanoform Enter into Agreement for Proof of Concept Collaboration

Herantis Pharma Oyj Announces Nomination Committee Appointments

Herantis Pharma plc Appoints Magnus Sjögren as Chief Medical Officer, Effective May 1, 2021

Herantis Pharma Oyj to Report Fiscal Year 2020 Final Results on Mar 25, 2021

New 90-day low: €3.90

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® Trial in Breast Cancer Associated Lymphedema

New 90-day low: €4.83

Ingrid Heiman to Leave Herantis Pharma's Board of Directors

Herantis Pharma Plc Appoints Tone Kvåle as Member of the Management Team

New 90-day low: €6.82

New 90-day low: €7.24

Herantis Pharma Oyj to Report Fiscal Year 2020 Results on Mar 03, 2021

New 90-day high - €8.86

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin